Governing the Genetic Age: Mechanism-Based Safety for Rapidly Expanding Technologies

The 1975 Asilomar Conference established safety principles for synthetic DNA technologies. Today, lipid-nanoparticle-encapsulated nucleic acids globally circumvent those principles. This stems not from emergency measures, but from misapplying outdated vaccine classifications to gene-transfer technologies.Classifying infectious-disease-targeted gene-transfer technologies as vaccines exempts them from mandatory pharmacokinetic and genotoxicity studies. This unjustified exemption now standardizes routine use in healthy populations, relying on assumptions lacking mechanism-informed data on distribution, persistence, and genomic interactions.We propose “Asilomar 2027”—a global summit establishing: (i) regulatory classification based on biological mechanisms, not intended-use labels; (ii) preclinical verification aligned with biological reality; (iii) shifting the evidentiary burden to manufacturers to prospectively prove safety via auditable data before deployment; and (iv) independent international oversight.This framework couples innovation with biology, restoring the rigorous safety standards essential for sustainable medical progress.